Seraph® 100 Microbind® utilization in immunocompromised toddler with adenovirus viremia in conjunction with continuous renal replacement therapy and extracorporeal membrane oxygenation
The Seraph® 100 Microbind® is an extracorporeal, sorbent hemoperfusion device intended to adsorb pathogens when integrated into extracorporeal circuits. We describe the use of Seraph 100 in an 18-month-old immunocompromised toddler with adenovirus viremia in conjunction with continuous renal replacement therapy and extracorporeal membrane oxygenation.
Authors
- James Gaensbauer (ORCID: https://orcid.org/0000-0002-0732-4150)
- Emily R. Levy (ORCID: https://orcid.org/0000-0001-8447-7663)
- Guyu Li (ORCID: https://orcid.org/0000-0002-0729-8933)
- Wendy Allen‐Rhoades (ORCID: https://orcid.org/0000-0002-5656-9568)
- Mira A. Kohorst (ORCID: https://orcid.org/0000-0002-1865-7444)
- Charlotte S. Van Dorn (ORCID: https://orcid.org/0000-0001-7931-4982)
- Christian Hanna (ORCID: https://orcid.org/0000-0002-9956-8696)
- Laura Dinnes
- Ziyuan Zhang (ORCID: https://orcid.org/0000-0003-3488-5903)
Institutions
- Mayo Clinic (US)
- Harvard University (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- IDCases
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.idcr.2025.e02380
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00